Key Factor Supporting Diverticulitis Disease Market Development in 2025: Smoking's Role In Fueling Diverticulitis Market Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Diverticulitis Disease Market Size By 2025?
The market size for the diverticulitis disease has experienced swift expansion recently. It is projected to escalate from $1.85 billion in 2024 to $2.04 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.1%. Factors such as an aging population, food consumption patterns, obesity, and improvements in medical imaging are contributing to the growth observed in the historical period.

How Big Is the Diverticulitis Disease Market Size Expected to Grow by 2029?
Expectations are high for the diverticulitis disease market size to experience significant growth in the ensuing years. It is projected to reach $2.92 billion by 2029, with a compound annual growth rate (CAGR) of 9.4%. The growth within the forecasted period can be associated with factors such as the prevalence of colonoscopy and endoscopy, heightened awareness, the rise of minimally invasive procedures, and tailored medical treatments. Key trends to look out for during this period encompass preventive strategies, the improvement of diagnostic tools, the incorporation of collaborative care models, and changes in healthcare policies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Which Key Market Drivers Powering Diverticulitis Disease Market Expansion and Growth?
The escalating pattern of smoking is predicted to stimulate the expansion of the diverticulitis disease market. Factors such as forceful advertising, social acceptance, stress, and nicotine's addictive quality all contribute to this rising trend of smoking addiction. Furthermore, the accessibility of e-cigarettes and vaping devices, as well as social influences and peer pressure, particularly among young people, are increasing the rates of smoking. Smoking heightens the growth of diverticulitis treatment by increasing diverticular disease risk since it impairs blood supply to the colon, potentially leading to more serious complications. This situation, in turn, creates a heightened demand for diagnostic and therapeutic options. For illustration, Statistics Canada reported in July 2022 that cigarette production went up by 5.8% in contrast to June 2021 and also, the total quantity of cigarettes sold escalated by 1.3% from May 2022, reaching 1.4 billion in June 2022. Thus, the growth of the diverticulitis disease market is fueled by the increasing prevalence of smoking addiction. The escalating incidence of diabetes is projected to stimulate the diverticulitis disease market's expansion. Contributing factors to the increasing prevalence of diabetes range from unhealthy diets rich in processed foods, lack of physical activity, rising obesity figures, genetic tendencies, and an aging populace. Diabetes can enhance diverticulitis treatment growth by creating a higher risk of complications like weakened blood vessels, which can make the colon more vulnerable to infections and inflammation, thereby driving a higher demand for treatments and therapies. For instance, The National Health Service (NHS England) reported in June 2024 that the number of individuals identified as pre-diabetic by the NHS in England surged to 3,615,330 in 2023, indicating an increase of 18% from 3,065,825 in 2022. Moreover, the figure rose nearly 25% among those under 40, growing from 173,166 in 2022 to 216,440 in 2023. Hence, the growing prevalence of diabetes propels the diverticulitis disease market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12990&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Diverticulitis Disease Market?
Notable companies in the diverticulitis disease arena are focusing on developing novel drug solutions and procuring their validation to solidify their market standing. The creation of these drugs potentially paves way to more efficacious solutions for diverticulitis management, minimizing complications and enhancing patient recovery. For instance, Seres' microbiota drug for repeated gut infections achieved a nod of approval from the United States Food and Drug Administration, a federal entity in the U.S., in April 2023. This medication concentrated on treating repetitive gut infections and impeding the recurrence of Clostridioides difficile (C. diff) infections among adults 18 or older. The authorization for Vowst was grounded on a clinical research involving 346 patients with recurring CDI. The research outcomes demonstrated that the Vowst recipients were considerably less inclined to another bout of the infection as opposed to their placebo counterparts. The Firmicutes spores-containing microbiota-based orally-administered drug is deemed essential for a robust microbiome that can fend off C.diff colonization.

What Are the Emerging Segments in the Diverticulitis Disease Market?
The diverticulitis disease market covered in this report is segmented -

1) By Type: Uncomplicated, Complicated
2) By Diagnosis: Computed Tomography (CT) Scan, Ultrasound, Urine Test, Blood Test
3) By Treatment: Medications, Surgery, Supportive care, Penicillin Antibiotic, Antibiotics, Dietary Supplements, Intravenous (IV) Fluids
4) By End-User: Specialty Centers, Hospitals, Research centers

Subsegments:
1) By Uncomplicated: Outpatient Treatment, Dietary Management, Antibiotic Therapy
2) By Complicated: Hospitalization, Surgical Intervention, Intravenous Antibiotics, Abscess Drainage

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12990&type=smp

Who Are the Global Leaders in the Diverticulitis Disease Market?
Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

Which are the Top Profitable Regional Markets for the Diverticulitis Disease Industry?
North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12990

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.